- Home
- TNGX vs VKTX Comparison
TNGX vs VKTX Comparison
Compare TNGX & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TNGX | VKTX |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.3B |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | TNGX | VKTX |
|---|---|---|
| Price | $20.23 | $28.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 7 |
| Target Price | $21.78 | ★ $95.86 |
| AVG Volume (30 Days) | ★ 2.5M | 1.7M |
| Earning Date | 05-08-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 26.89 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $62,384,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 48.29 | N/A |
| 52 Week Low | $3.77 | $22.96 |
| 52 Week High | $28.41 | $43.15 |
Technical Indicators
Market Signals| Indicator | TNGX | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.30 | 36.64 |
| Support Level | $6.77 | $25.77 |
| Resistance Level | $22.01 | $36.77 |
| Average True Range (ATR) | 1.47 | 1.25 |
| MACD | -0.06 | -0.14 |
| Stochastic Oscillator | 6.95 | 0.19 |
Price Performance
Historical ComparisonAbout TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.